CSL, AU000000CSL8

CSL stock: Sydney gains 0.96 percent ahead of the Xetra open

Published on 10/19/2026 at 08:07 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
In Sydney, CSL shares rose 0.96 percent on October 19, 2026. At Lang & Schwarz the stock trades pre-market at EUR 119.13 on October 19, 2026.

Sydney Trading Sets Context

  • CSL shares gained 0.96 percent in Sydney on October 19, 2026.
  • CSL operates through two principal segments, CSL Behring and CSL Seqirus.
  • CSL stock trades pre-market at EUR 119.13 at 8:03 a.m. CEST at Lang & Schwarz on October 19, 2026.
CSL, AU000000CSL8, Illustration mit AI erstellt.

CSL's ASX-listed shares rose 0.96 percent to AUD 194.05 in Sydney on October 19, 2026. CSL stock trades pre-market at EUR 119.13 at 8:03 a.m. CEST at Lang & Schwarz on October 19, 2026.

Sydney session provides context

The Australian-listed shares were quoted at AUD 194.05 after the Sydney session on October 19, 2026. The move in Australia is presented separately from the euro indication in Germany.

Ahead of the Xetra open

The Lang & Schwarz bid was EUR 118.52 and the ask EUR 119.74, a spread of 1.02 percent. The further course from the Xetra open at 9:00 a.m. CET/CEST is shown by the continuously updated real-time quote of CSL stock.

How CSL makes its money

CSL operates as a biopharmaceutical company that researches, develops, manufactures, markets and distributes pharmaceutical and allied products. Its two principal operating segments are CSL Behring, focused on plasma-derived and recombinant therapies, and CSL Seqirus, which develops and distributes non-plasma biotherapeutic and influenza-related products. Market context: Market report S&P/ASX 200.

More news and analysis on CSL stock

Disclaimer...
en | AU000000CSL8 | CSL | boerse | 70358143 | bgmi